Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8582637 | 1.00 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2CES2CES1HSD11B1 | |
| SCHEMBL453057 | 0.98 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2CES2CES1HSD11B1 | |
| SCHEMBL3152795 | 0.94 | SMN1; SMN2 (0.39) | ALDH1A1SMN1; SMN2KMT2AADRB2ADRB1 | |
| SCHEMBL8694628 | 0.90 | — | — | |
| SCHEMBL450922 | 0.85 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2CES2CES1HSD11B1 | |
| SCHEMBL8584525 | 0.85 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2CES2CES1HSD11B1 | |
| SCHEMBL449505 | 0.82 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2CES2CES1HSD11B1 | |
| SCHEMBL9205374 | 0.81 | GABRP (0.42) | ALDH1A1SMN1; SMN2POLBKMT2AMEN1 | |
| SCHEMBL11041019 | 0.79 | NAAA (0.40) | ALDH1A1NAAAEPHX1 | |
| SCHEMBL8845360 | 0.78 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2CES2CES1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 690 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131032-A1 | NEUROTHERAPEUTIC TREATMENT FOR SEXUAL DYSFUNCTION | REVAAX PHARMACEUTICALS, LLC (US) | 2013-05-23 | — | — | US | claimed |
| US-7355040-B2 | Process for the preparation of cephalosporin compounds and synthetic intermediates | ZOETIS SERVICES LLC | 2008-04-08 | — | — | US | claimed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| EP-0338824-A2 | Esters of 6-beta-(alpha-oxyimino)-acylamino-penicillanic acid derivatives | BEECHAM GROUP PLC (GB) | 1989-10-25 | — | — | EP | claimed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024064209-A1 | COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS | DATA2DISCOVERY, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| CN-114615999-B | Drug antibody conjugates | 法马马有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| CN-116327950-A | Use of a composition for the treatment of neuropsychiatric symptoms of neurodegenerative diseases | 阿泽范药品公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116139282-A | Compositions and methods for treating neurodegenerative diseases | 阿泽范药品公司 | 2023-05-23 | — | — | CN | disclosed |
| US-4835150-A | ANTIBIOTICS | BEECHAM GROUP P.L.C. (GB) | 1989-05-30 | — | — | US | disclosed |
| US-4820701-A | Penam derivatives | BEECHAM GROUP P.L.C. (GB) | 1989-04-11 | — | — | US | disclosed |
| EP-0308559-A2 | Cephalosporins, process for their preparation, pharmaceutical compositions containing them and intermediates | BEECHAM GROUP PLC (GB) | 1989-03-29 | — | — | EP | disclosed |
| US-4816452-A | ANTIBIOTICS | BEECHAM GROUP P.L.C. (GB) | 1989-03-28 | — | — | US | disclosed |
| EP-0293532-A1 | 6- or 7-beta-[2-[4-(substituted)-2,3-dioxopiperazin-1-yl) carbonylamino]-(substituted)acetamido]-penicillin and cephalosporin derivatives | BEECHAM GROUP PLC (GB) | 1988-12-07 | — | — | EP | disclosed |
| EP-0254582-A2 | 6 Beta-(alpha-oximino)-acylamino penicillanic-acid derivatives and starting compounds | BEECHAM GROUP PLC (GB) | 1988-01-27 | — | — | EP | disclosed |
| EP-0219926-A2 | Cephalosporins, processes for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1987-04-29 | — | — | EP | disclosed |
| US-4477447-A | ANTIBIOTIC, BACTERICIDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | ALDH1A1 1429/4885SMN1; SMN2 114/4885CES2 197/4885 |
| US-20130131032-A1 | NEUROTHERAPEUTIC TREATMENT FOR SEXUAL DYSFUNCTION | PREP, DNPEP, PRSS12 | ALDH1A1 1573/4885SMN1; SMN2 518/4885CES2 95/4885 |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | ALDH1A1 785/4885SMN1; SMN2 3089/4885CES2 2410/4885 |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | B3GAT3, MGAT3, SDAD1 | ALDH1A1 162/4885SMN1; SMN2 4523/4885CES2 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.